FDAnews
www.fdanews.com/articles/82142-nabi-announces-results-of-staphvax-confirmatory-phase-iii-trial

NABI ANNOUNCES RESULTS OF STAPHVAX CONFIRMATORY PHASE III TRIAL

November 2, 2005

Nabi Biopharmaceuticals has announced that its StaphVAX (staphylococcus aureus polysaccharide conjugate vaccine) failed to meet its primary endpoint in the company's confirmatory Phase III clinical trial.

The study, a randomized, double-blinded, placebo-controlled trial of 3,600 patients on hemodialysis, found no reduction in S. aureus Types 5 and 8 infections in the StaphVAX group as compared to the placebo group. The company will immediately initiate an assessment to determine the factors causing this outcome, including the vaccine target (S. aureus polysaccharide capsule) and the quality of the antibody generated by the vaccine.

The company will also halt the development of Altastaph (staphylococcus aureus immune globulin intravenous) its investigational product for the prevention and treatment of S. aureus infections, as it is based on the same capsular polysaccharide technology as StaphVAX.